Zimbabwe has turned down a substantial US health deal worth 367 million US dollars (£272m) over five years because of Washington's demand for confidential data.
This rejection came to light after a government memo from December was leaked, revealing that President Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government spokesperson has since stated that the US was seeking biological samples for research and commercial purposes but was unwilling to guarantee the resulting advantages from future vaccines.
"We are forced to start the challenging and unfortunate task of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for further talks to reach a agreement suitable to all parties so the country's vital HIV programme can proceed.
Broader Context
This development comes after a comparable situation in Kenya, where a high court halted a related health funding agreement after legal challenges were raised about the safety of citizens' health data.
Since returning to office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral agreements to enhance openness and accountability.
Based on statements, 16 nations in Africa have to date signed similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment through US-supported programmes," the Ambassador said.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, without any corresponding guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Effectively, our nation would supply the basic resources for medical research with no certainty that the end products would be accessible to our citizens should a new disease outbreak arise."
Sovereignty and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were disrupting structures previously set up via the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing system designed to deal with potential global health emergencies.
"This framework is designed to ensure that when a country contributes its information, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome continued discussions with our American counterparts on how future collaboration could be structured in a way that respects the independence and dignity of both nations."
Health Experts Response
Medical experts stated it acknowledged the government's concerns, but recommended that negotiations must proceed considering a large portion of the nation's Aids initiatives were funded by international support.
"Where specific concerns exist, such as those involving data governance or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," the group commented.
The situation highlights the complex challenges between accepting crucial international aid and protecting local interests in an increasingly data-driven world.